CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Recruiting · NCT05029999 · Registry updated 2026-06-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 1 | 2026-06-17 | NCT05029999 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Celldex Therapeutics | 13 |
| Gateway for Cancer Research | 32 |
| National Cancer Institute (NCI) | 3015 |
| University of Texas Southwestern Medical Center | 295 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Johns Hopkins University | Baltimore | United States | 150 |
| Sarah Cannon Research Institute | Nashville | United States | 119 |
| Texas Oncology, P.A. | Dallas | United States | 2 |
| The University of Texas Health Science Center at San Antonio | San Antonio | United States | 26 |
| University of Chicago Comprehensive Cancer Center | Chicago | United States | 273 |
| University of North Carolina | Chapel Hill | United States | 101 |
| UT Southwestern Medical Center | Dallas | United States | 210 |